Mrs
Dr
Miss
Ms
Prof
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/1934486
Miripla - Analysis and Market Forecasts from 2010 to 2020
Description:
Miripla – Analysis and Market Forecasts from 2010 to 2020
Summary
GlobalData’s pharmaceuticals report, “Miripla – Analysis and Market Forecasts from 2010 to 2020” provides Miripla sales estimates for Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2010-2020). The report also includes information on Liver Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for Japan
- Analysis and review of Miripla including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Miripla including efficacy, safety, pricing and other details which influence its sales potential
- Detailed sales forecast for 2010-2020 for Miripla in Japan
-
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Summary
GlobalData’s pharmaceuticals report, “Miripla – Analysis and Market Forecasts from 2010 to 2020” provides Miripla sales estimates for Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2010-2020). The report also includes information on Liver Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for Japan
- Analysis and review of Miripla including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Miripla including efficacy, safety, pricing and other details which influence its sales potential
- Detailed sales forecast for 2010-2020 for Miripla in Japan
-
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Contents:
1 Table of contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Liver Cancer Market
2.2 Epidemiology
2.3 Etiology
2.3.1 Hepatitis B Infection
2.3.2 Hepatitis C Infection
2.3.3 Alcohol
2.3.4 Aflatoxin B1
2.3.5 Hemochromatosis
2.3.6 Diabetes and Obesity
2.3.7 Cirrhosis
2.4 GlobalData Report Guidance
3 Liver Cancer : Market Characterization
3.1 Liver Cancer Market
3.2 Liver Cancer Market Forecasts and CAGR
3.3 Drivers for the Liver Cancer Market
3.3.1 High Incidence
3.3.2 High Mortality
3.3.3 Large Unmet Need
4 Tumor–Node–Metastases (TNM) Classification of Liver Cancer
5 Miripla
5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Studies
5.3.1 Phase II/III Trials
5.3.2 Phase II Trials
5.3.3 Phase I Trials
5.4 Approval History of Miripla
5.5 Factors Affecting Sales of Miripla
5.5.1 Method of Administration
5.5.2 Low Competition
5.5.3 Lack of Presence in the US and EU Market
5.6 Drug Risk Benefit Score
5.6.1 Efficacy
5.6.2 Safety
5.6.3 Compliance
5.6.4 Dosing Convenience
5.7 Intensity of Competition
5.8 Sales Forecast
5.8.1 Target Patient Pool of Miripla
5.8.2 Dosing
5.8.3 Market Penetration
5.8.4 Annual Cost of Therapy
5.8.5 Sales Projections of Miripla
6 Liver Cancer Market: Appendix
6.1 Market Definitions
6.2 List of Abberiviations
6.3 Research Methodology
6.3.1 Coverage
6.3.2 Secondary Research
6.3.3 Forecasting
6.3.4 Number of Patients Approved to take the Drug
6.3.5 Net Penetration of Drug
6.3.6 Net Annual Dosing
6.3.7 Annual Cost of Therapy
6.3.8 Primary Research
6.3.9 Expert Panels
6.4 Drug Sales Estimates Model
6.5 Contact Us
6.6 Disclaimer
6.7 Sources
1.1 List of Tables
Table 1: Liver Cancer, Incidences and Mortality, 2008–2030
Table 2: Drug Risk Benefit Score of Miripla
Table 3: Miripla, Liver Cancer, Japan, Estimated Sales ($m), 2010–2020
1.2 List of Figures
Figure 1: Fatality = [(% Distribution of Incidence) –(% Distribution Mortality )] of Most Common Cancers
Figure 2: Liver Cancer, Global, Market Size Forecast ($m), 2010–2020
Figure 3: Liver Cancer, Worldwide, Incidence (in millions), 2008–2030
Figure 4: Oncology, Worldwide, Incidence (in millions), 2008–2030
Figure 5: Liver Cancer, Worldwide, Mortality (in millions), 2008–2030
Figure 6: Classification of Liver Cancer
Figure 7: Drug Model Diagram of Miripla
Figure 8: Miripla, Liver Cancer, Japan, Estimated Sales ($m), 2010–2020
Figure 9: Drug Model Diagram
Figure 10: Patients Approved for the Drug
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Liver Cancer Market
2.2 Epidemiology
2.3 Etiology
2.3.1 Hepatitis B Infection
2.3.2 Hepatitis C Infection
2.3.3 Alcohol
2.3.4 Aflatoxin B1
2.3.5 Hemochromatosis
2.3.6 Diabetes and Obesity
2.3.7 Cirrhosis
2.4 GlobalData Report Guidance
3 Liver Cancer : Market Characterization
3.1 Liver Cancer Market
3.2 Liver Cancer Market Forecasts and CAGR
3.3 Drivers for the Liver Cancer Market
3.3.1 High Incidence
3.3.2 High Mortality
3.3.3 Large Unmet Need
4 Tumor–Node–Metastases (TNM) Classification of Liver Cancer
5 Miripla
5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Studies
5.3.1 Phase II/III Trials
5.3.2 Phase II Trials
5.3.3 Phase I Trials
5.4 Approval History of Miripla
5.5 Factors Affecting Sales of Miripla
5.5.1 Method of Administration
5.5.2 Low Competition
5.5.3 Lack of Presence in the US and EU Market
5.6 Drug Risk Benefit Score
5.6.1 Efficacy
5.6.2 Safety
5.6.3 Compliance
5.6.4 Dosing Convenience
5.7 Intensity of Competition
5.8 Sales Forecast
5.8.1 Target Patient Pool of Miripla
5.8.2 Dosing
5.8.3 Market Penetration
5.8.4 Annual Cost of Therapy
5.8.5 Sales Projections of Miripla
6 Liver Cancer Market: Appendix
6.1 Market Definitions
6.2 List of Abberiviations
6.3 Research Methodology
6.3.1 Coverage
6.3.2 Secondary Research
6.3.3 Forecasting
6.3.4 Number of Patients Approved to take the Drug
6.3.5 Net Penetration of Drug
6.3.6 Net Annual Dosing
6.3.7 Annual Cost of Therapy
6.3.8 Primary Research
6.3.9 Expert Panels
6.4 Drug Sales Estimates Model
6.5 Contact Us
6.6 Disclaimer
6.7 Sources
1.1 List of Tables
Table 1: Liver Cancer, Incidences and Mortality, 2008–2030
Table 2: Drug Risk Benefit Score of Miripla
Table 3: Miripla, Liver Cancer, Japan, Estimated Sales ($m), 2010–2020
1.2 List of Figures
Figure 1: Fatality = [(% Distribution of Incidence) –(% Distribution Mortality )] of Most Common Cancers
Figure 2: Liver Cancer, Global, Market Size Forecast ($m), 2010–2020
Figure 3: Liver Cancer, Worldwide, Incidence (in millions), 2008–2030
Figure 4: Oncology, Worldwide, Incidence (in millions), 2008–2030
Figure 5: Liver Cancer, Worldwide, Mortality (in millions), 2008–2030
Figure 6: Classification of Liver Cancer
Figure 7: Drug Model Diagram of Miripla
Figure 8: Miripla, Liver Cancer, Japan, Estimated Sales ($m), 2010–2020
Figure 9: Drug Model Diagram
Figure 10: Patients Approved for the Drug
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1582661
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Printed Wednesday, May 22, 2013
12:13:30 PM
12:13:30 PM
Fax order form
To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
Product name
Miripla - Analysis and Market Forecasts from 2010 to 2020
Web Address
http://www.researchandmarkets.com/reports/1934486
Office Code
OC8DIQSPMTRXWY
Report Formats
Please enter the quantity of the report format you require.
| Format | Quantity | Price | Electronic (PDF) - Site License |
|
EURO€ 3,075.00 |
|---|---|---|
| Electronic (PDF) - Single User |
|
EURO€ 1,537.00 |
| Electronic (PDF) - Enterprisewide |
|
EURO€ 4,612.00 |
Contact information
Please enter all the information below in block capitals.
Title:
Mr
Mrs
Dr
Miss
Ms
Prof
Mrs
Dr
Miss
Ms
Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Page 2 of 2
Printed Wednesday, May 22, 2013
12:13:30 PM
12:13:30 PM
Payment information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Pay by Wire Transfer:
Please transfer funds to:
Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp